bioAffinity Technologies Publishes Sputum Processing and Innovative High-Throughput Analysis Methods

PUBLISHED ON August 12, 2021

August 12, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized Experiments (JoVE). The paper, entitled Quality-Controlled Sputum Analysis by Flow Cytometry, presents an efficient and effective method to analyze sputum on a flow cytometric platform, allowing for development of high-throughput diagnostic tests for lung cancer and other lung diseases.

bioAffinity Technologies Presents Scientific Discoveries Advancing Cancer Therapeutics and Diagnostics at Two Global Conferences

PUBLISHED ON June 23, 2021

June 23, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, will present the Company’s discoveries in the field of cancer diagnostics and therapeutics at the RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium June 23 – 25, 2021, and the International Conference on Porphyrins and Phthalocyanines (ICPP) June 28 – July 3, 2021.

Fed change in cancer screening could nearly double SA biotech’s growth

PUBLISHED ON March 20, 2021

San Antonio Business Journal (March 19, 2021) Several major national medical groups are calling on the Centers for Medicare & Medicaid Services to update lung cancer screening coverage to significantly expanding access to such tests.

Leading Cell Biology Journal Publishes bioAffinity Technologies’ Groundbreaking Research on Porphyrins

PUBLISHED ON March 3, 2021

March 3, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced that a scientific paper that explains how porphyrins are selectively incorporated into cancer cells has been published in the Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal).

SA biotech pursuing deal to access $5B China market

PUBLISHED ON February 11, 2021

San Antonio Business Journal (February 8, 2021) “China represents a $5 billion market for CyPath^© Lung. An estimated 780,000 people will be diagnosed annually in China with lung cancer, most often at late stage,” bioAffinity President and CEO Maria Zannes said. "Fosun Long March is a driving force in health care, bringing medical breakthroughs to China and the world that improve the health and clinical outcomes of patients.”